# Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

> **NCT03477175** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 40 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** E7080
- **DRUG:** Comparator Drug
- **DRUG:** Comparator Drug: Sorafenib

## Key facts

- **NCT ID:** NCT03477175
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-16
- **Primary completion:** 2023-12-21
- **Final completion:** 2023-12-21
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03477175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03477175, "Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03477175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*